<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(10)</volume><submitter>Whigham M</submitter><pubmed_abstract>The Banff classification scheme provides a framework for interpreting transplant kidney biopsies and has undergone various updates in the past 2 decades especially related to antibody-mediated rejection. The clinical significance of early glomerulitis seen within 4 mo on protocol biopsies has received limited attention. We hypothesized that early glomerulitis seen on protocol biopsies will lead to significant adverse outcomes as assessed by histopathology and allograft outcome.&lt;h4>Methods&lt;/h4>A single-center retrospective study of a cohort of patients who underwent protocol biopsies within 4 mo after transplantation with timely follow-up protocol biopsies were assessed. Patients with recurrent glomerulonephritis were excluded.&lt;h4>Results&lt;/h4>We calculated glomerulitis (g) scores for 2212 biopsy specimens and identified 186 patients with glomerulitis (g > 0) and 2026 patients without glomerulitis (g = 0). The progression to chronic transplant glomerulopathy at 1 and 2 y was higher in patients with g > 0 as compared with g = 0 (year 1, 10.7% versus 2.3% [&lt;i>P&lt;/i> &lt; 0.001]' respectively; year 2, 17.2% versus 4.3% [&lt;i>P&lt;/i> &lt; 0.001], respectively) with no difference in other chronic lesions. The death-censored graft failure rate was higher in patients with g > 0 as compared with g = 0 (hazard ratio, 1.68 [95% CI, 1.07-2.65]; &lt;i>P&lt;/i> = 0.02). We did not find any difference in outcomes in glomerulitis group based on donor-specific antibody.&lt;h4>Conclusion&lt;/h4>Our findings suggest that early glomerulitis (seen within 4 mo after transplantation) may lead to clinically significant long-term changes and thus could be a target for early intervention therapies.</pubmed_abstract><journal>Transplantation direct</journal><pagination>e1381</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9529059</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Impact of Glomerulitis on Long-term Outcomes After Kidney Transplantation.</pubmed_title><pmcid>PMC9529059</pmcid><pubmed_authors>Ryan MS</pubmed_authors><pubmed_authors>Lim ES</pubmed_authors><pubmed_authors>Whigham M</pubmed_authors><pubmed_authors>Ramon DS</pubmed_authors><pubmed_authors>Mour GK</pubmed_authors><pubmed_authors>Nair SS</pubmed_authors><pubmed_authors>Heilman RL</pubmed_authors><pubmed_authors>Jaramillo A</pubmed_authors><pubmed_authors>Buras MR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Impact of Glomerulitis on Long-term Outcomes After Kidney Transplantation.</name><description>The Banff classification scheme provides a framework for interpreting transplant kidney biopsies and has undergone various updates in the past 2 decades especially related to antibody-mediated rejection. The clinical significance of early glomerulitis seen within 4 mo on protocol biopsies has received limited attention. We hypothesized that early glomerulitis seen on protocol biopsies will lead to significant adverse outcomes as assessed by histopathology and allograft outcome.&lt;h4>Methods&lt;/h4>A single-center retrospective study of a cohort of patients who underwent protocol biopsies within 4 mo after transplantation with timely follow-up protocol biopsies were assessed. Patients with recurrent glomerulonephritis were excluded.&lt;h4>Results&lt;/h4>We calculated glomerulitis (g) scores for 2212 biopsy specimens and identified 186 patients with glomerulitis (g > 0) and 2026 patients without glomerulitis (g = 0). The progression to chronic transplant glomerulopathy at 1 and 2 y was higher in patients with g > 0 as compared with g = 0 (year 1, 10.7% versus 2.3% [&lt;i>P&lt;/i> &lt; 0.001]' respectively; year 2, 17.2% versus 4.3% [&lt;i>P&lt;/i> &lt; 0.001], respectively) with no difference in other chronic lesions. The death-censored graft failure rate was higher in patients with g > 0 as compared with g = 0 (hazard ratio, 1.68 [95% CI, 1.07-2.65]; &lt;i>P&lt;/i> = 0.02). We did not find any difference in outcomes in glomerulitis group based on donor-specific antibody.&lt;h4>Conclusion&lt;/h4>Our findings suggest that early glomerulitis (seen within 4 mo after transplantation) may lead to clinically significant long-term changes and thus could be a target for early intervention therapies.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Oct</publication><modification>2025-04-04T09:24:25.082Z</modification><creation>2025-04-04T09:24:25.082Z</creation></dates><accession>S-EPMC9529059</accession><cross_references><pubmed>36204188</pubmed><doi>10.1097/TXD.0000000000001381</doi></cross_references></HashMap>